The San Diego company also lowered its financial guidance for 2025 in response to China’s import restrictions.

Illumina will seek to cut $100 million in expenses by the end of this fiscal year as it plans to deal with a loss of revenue ...

We recently published an article titled Why These 15 Large-Cap Stocks Are Plunging So Far In 2025. In this article, we are ...

Illumina slashes costs by $100 million after China bans its sequencers. The company lowers its 2025 EPS outlook and aims for ...

Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company") today responded to the March 4, 2025 notice from the China Ministry of Commerce ("MOFCOM") that Illumina is not permitted to export ...

Illumina on Monday lowered its annual forecast and said it plans to cut $100 million in spending after China announced a ban ...

China imposed an import ban on Illumina’s gene sequencers in response to President Trump’s escalating tariffs and trade war ...

Illumina Inc. (NASDAQ:ILMN), a leading provider of next-generation sequencing (NGS) technology with annual revenue of $4.37 billion, finds itself at a critical juncture as it navigates a shifting ...

In a report released yesterday, Conor McNamara from RBC Capital maintained a Buy rating on Illumina (ILMN – Research Report), with a price ...

Illumina (ILMN) said it is instituting an incremental approximately $100M cost reduction program for fiscal 2025. The company added, “These ...

Illumina is not banned from operating in the country and will continue to serve its existing customers, a company ...

CRISPR Therapeutics' stock faces challenges with slow Casgevy adoption and competition. See how CRSP stock remains a cautious ...